Erythrina Caffra (Erythrina caffra 'Coral Tree')

Erythrina caffra, the South African Coral Tree, contains isoquinoline alkaloids including erysotrine and erythraline that interact with GABA-A receptors and acetylcholine pathways to produce sedative and anxiolytic effects. Research on closely related Erythrina species suggests these alkaloids modulate cortisol secretion and inflammatory mediators, though direct clinical evidence specific to E. caffra remains limited.

Origin & History

Erythrina caffra ('Coral Tree') is a deciduous tree native to South Africa's coastal regions, belonging to the Fabaceae family and cultivated for its vibrant red flowers. The plant material (bark, leaves, roots) is harvested from wild or cultivated trees and processed through traditional extraction methods including decoctions, infusions, or ethanol extracts. As a member of the alkaloid-rich legume class, it contains isoquinoline alkaloids, flavonoids, tannins, and saponins similar to other Erythrina species.

Historical & Cultural Context

While E. caffra lacks detailed historical records, Erythrina species feature prominently in African traditional medicine (E. abyssinica used in Uganda and Kenya for gastrointestinal disorders and malaria) and Ayurvedic systems (E. indica for inflammation, fever, and anxiety since medieval times). These plants have been used for centuries in tribal folk medicine for inflammatory diseases, CNS disorders, and infections.

Health Benefits

• May reduce stress and anxiety markers based on related E. indica species showing cortisol reduction in human volunteers (evidence: preliminary human data)
• Potential anti-inflammatory effects when E. indica bark extract was combined with NSAIDs, showing enhanced benefits with fewer gastric side effects (evidence: small human trial)
• Traditional use for menstrual cramp relief, with E. indica pilot study showing 60% of women experiencing milder symptoms (evidence: limited pilot data)
• Possible antidiabetic properties demonstrated in E. abyssinica through in vitro and animal models (evidence: preclinical only)
• Wound healing and astringent effects attributed to tannin content across Erythrina species (evidence: traditional use and phytochemical analysis)

How It Works

The isoquinoline alkaloids in Erythrina caffra, particularly erysotrine and erythraline, act as competitive antagonists at nicotinic acetylcholine receptors (nAChRs) and are thought to potentiate GABA-A receptor activity, producing CNS depressant and anxiolytic effects. Bark extracts from related Erythrina species inhibit cyclooxygenase (COX-1 and COX-2) enzymes and suppress pro-inflammatory cytokines including TNF-α and IL-6, which may explain observed anti-inflammatory synergy with NSAIDs. Alkaloid-mediated modulation of the hypothalamic-pituitary-adrenal (HPA) axis has been proposed as the mechanism behind cortisol reduction observed in preliminary human studies using E. indica.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Erythrina caffra were identified; all evidence derives from related species or preclinical studies. A 2021 Phytomedicine study on E. indica reported stress marker reduction over 4 weeks, while a 2019 Fitoterapia trial showed enhanced anti-inflammatory effects when combined with NSAIDs (sample sizes unspecified, no PMIDs provided in sources).

Clinical Summary

Direct clinical trials on Erythrina caffra are absent from the published literature; existing human evidence derives primarily from E. indica studies, making extrapolation speculative. A small human volunteer study using E. indica bark extract reported measurable reductions in salivary cortisol under stress conditions, though sample sizes were limited and methodology details are not fully standardized. Combination studies pairing E. indica bark extract with NSAIDs in human subjects suggested enhanced anti-inflammatory outcomes with reduced gastric side effects compared to NSAIDs alone, representing preliminary but not confirmatory evidence. Overall, the evidence base is rated preliminary to preclinical, and robust randomized controlled trials specific to E. caffra have not been conducted.

Nutritional Profile

Erythrina caffra (Coral Tree) bark, seeds, and leaves contain a distinct alkaloid profile as the primary bioactive fraction. Erythrina alkaloids — including erythraline, erysotrine, erysovine, erysopine, and erythroidine — are present at approximately 0.1–0.5% dry weight in bark tissue, with β-erythroidine being pharmacologically notable as a nicotinic acetylcholine receptor antagonist. Seeds contain moderate protein (approximately 20–28% dry weight) with a leguminous amino acid profile, including lysine, arginine, and leucine, though seed consumption is generally discouraged due to toxic alkaloid concentration. Crude fiber content in bark preparations is estimated at 15–25% dry weight. Flavonoids including luteolin, apigenin, and quercetin glycosides are present in leaf and bark extracts at trace to low concentrations (estimated 0.05–0.2% dry weight). Isoflavones analogous to those found in related Erythrina species (e.g., calycosin, formononetin) have been tentatively identified, contributing to reported phytoestrogenic and anti-inflammatory activity. Mineral content in leaf material includes calcium (~1,200–1,800 mg/100g dry weight), potassium (~900–1,400 mg/100g dry weight), magnesium (~200–350 mg/100g dry weight), and iron (~15–30 mg/100g dry weight), consistent with other Erythrina species. Tannins and phenolic acids (e.g., gallic acid, caffeic acid derivatives) are present at approximately 2–5% dry weight in bark. Bioavailability of alkaloids is considered moderate via oral routes; flavonoid bioavailability is enhanced by gut microbial metabolism but overall limited due to glycosylation. Data specific to E. caffra is sparse; values are extrapolated primarily from E. indica and E. variegata research.

Preparation & Dosage

No clinically studied dosages exist for E. caffra specifically. Traditional doses from related E. indica include: bark powder 1-3 grams twice daily with water or honey for joint pain/fever; leaf decoction from 10-15g fresh leaves reduced to 100ml, taken as 50ml twice daily for anxiety/insomnia. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ashwagandha, Valerian root, White willow bark, Turmeric, Magnesium

Safety & Interactions

High doses of Erythrina alkaloids, including erysotrine and erythraline, can produce excessive CNS depression, muscle paralysis, and respiratory depression in animal models, suggesting a meaningful toxicity threshold that has not been clearly established in humans for E. caffra specifically. Due to nicotinic acetylcholine receptor antagonism, concurrent use with cholinergic medications, smoking cessation drugs (e.g., varenicline), or neuromuscular blocking agents carries a theoretical risk of additive or antagonistic interactions. Potentiation of benzodiazepines, barbiturates, or other CNS depressants is plausible given GABA-A receptor activity and should be avoided without medical supervision. Erythrina caffra is not evaluated for safety in pregnancy or lactation, and use should be avoided in these populations until adequate safety data exist.